Not provided
Not provided
Not provided
Not provided
A lot of patients recruited in our center were already on montelukast treatment. It was not possible to recruit sufficient patients for the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objectives of the study are:
1. To unravel the importance of molecular phenotyping in predicting the response to classical anti-asthma treatment (leukotriene antagonists)
The investigators have developed a non-invasive technique based on mRNA analysis of induced sputum that enables us to study airway inflammation in detail. This technique forms the basis for our current project based on the following hypotheses:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Montelukast | Active Comparator |
| |
| long-acting beta2-mimetic | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Montelukast | Drug | Montelukast, 10 mg |
| |
| long acting beta2 mimetic |
| Measure | Description | Time Frame |
|---|---|---|
| sputum cytokine mRNA | 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| responsiveness to the medication | 8 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dominique MA Bullens, MD,PhD | Lab of clinical immunology, O&N I Herestraat 49 - bus 811, 3000 Leuven, Belgiƫ | Principal Investigator |
| Sven F Seys, MSc | Lab of clinical immunology, O&N I Herestraat 49 - bus 811, 3000 Leuven, Belgiƫ | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital of Leuven | Leuven | Vlaams-Brabant | 3000 | Belgium |
Not provided
| ID | Term |
|---|---|
| C093875 | montelukast |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
ICS+long acting beta2 agonist: twice daily |
|